

GenScript, BioComo accelerate novel intranasal SARS-CoV-2 vaccine development in Japan

02 December 2021 | News

Currently global competition for nasal spray vaccines is intense to use as the 'next-generation vaccine'



GenScript Biotech Corporation, a leading global biotechnology company, and BioComo Incorporation, a drug discovery venture based in Mie prefecture, Japan, have announced a strategic agreement for joint research and development project on GenScript's cPass™ SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit as the in vitro neutralization assay of a BC-PIV derived SARS-Cov-2 vaccine.

GenScript will be responsible for providing cPass™ sVNT Kit and technical expertise for vaccine evaluation. The two companies are working together to expand sVNT utilities for SARS-CoV-2 vaccine development in Japan.

BC-PIV, an innovative non-transmissible viral vector co-developed by BioComo and Mie University, is derived from the recombinant human parainfluenza virus type 2 (hPIV2). BC-PIV, an intranasal vaccine against SARS-CoV-2, induced high levels of neutralizing IgG and mucosal IgA antibodies against the spike protein, completely protected the lungs and virtually complete protection of the nasal turbinates against SARS-CoV-2 challenge in hamsters. The intranasal BC-PIV vaccine can be a promising vaccine candidate to combat SARS-CoV-2 infection/transmission.